High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Journal of Clinical Oncology · 20.08.2026 · 44 (24) · 2290-2302
DOI: 10.1200/jco-26-00947 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2026. Verfasst von Matthew R Wilson und 38 weiteren Autor:innen. Beteiligte Einrichtung: Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Methotrexate, Central Nervous System Neoplasms, Lymphoma, Large B-Cell, Diffuse, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months. RESULTS Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% v 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% v 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% v 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]). CONCLUSION To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
- Sir Charles Gairdner Hospital, Perth, WA, Australia.
- CR UK and UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom.
- University College London Hospital, London, United Kingdom.
- Medical School, University of Western Australia, Perth, WA, Australia.
- Aalborg University Hospital, Aalborg, Denmark.
ORCID-Profile: Matthew R Wilson, Katharine L Lewis, Kate Cwynarski, Chan Y Cheah, Diego Villa, Kerry J Savage, Paola Ghione, Karin E Smedby, Sara Harrysson, Marek Trneny, Robert Puckrin, Christopher P Fox, Gita Thanarajasingam, Nicole Wong Doo, Greg Hapgood, Carole Soussain, Sylvain Choquet, Michael Dickinson, Dipti Talaulikar, Gavin Preston, Matthew Ahearne, Eliza A Hawkes, Elisabeth Schorb, Aline Clavert, Matthew Ku, Mayur Narkhede, Teresa Calimeri, Eric Durot, Jeffrey Smith, Loïc Renaud, Pamela McKay, Toby A Eyre
Förderung
- NCI NIH HHS
Zitieren
APA
Wilson, M. R., Lewis, K. L., Kirkwood, A. A., Cwynarski, K., Cheah, C. Y., El-Galaly, T. C., Villa, D., Savage, K. J., Ghione, P., Bobillo, S., Smedby, K. E., Harrysson, S., Trneny, M., Klanova, M., Puckrin, R., Fox, C. P., Bishton, M., Thanarajasingam, G., Wong Doo, N., …, & Eyre, T. A. (2026). High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis. Journal of Clinical Oncology, 44(24), 2290-2302. https://doi.org/10.1200/jco-26-00947
Vancouver
Wilson MR, Lewis KL, Kirkwood AA, Cwynarski K, Cheah CY, El-Galaly TC, et al. High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis. Journal of Clinical Oncology. 2026;44(24):2290-2302. doi:10.1200/jco-26-00947
BibTeX
@article{Wilson2026,
author = {Wilson, Matthew R and Lewis, Katharine L and Kirkwood, Amy A and Cwynarski, Kate and Cheah, Chan Y and El-Galaly, Tarec C and Villa, Diego and Savage, Kerry J and Ghione, Paola and Bobillo, Sabela and Smedby, Karin E and Harrysson, Sara and Trneny, Marek and Klanova, Magdalena and Puckrin, Robert and Fox, Christopher P and Bishton, Mark and Thanarajasingam, Gita and Wong Doo, Nicole and Hapgood, Greg and Soussain, Carole and Choquet, Sylvain and Dickinson, Michael and Talaulikar, Dipti and de Mel, Sanjay and Preston, Gavin and Ahearne, Matthew and Hawkes, Eliza A and Schorb, Elisabeth and Clavert, Aline and Ku, Matthew and Guidetti, Anna and Narkhede, Mayur and Calimeri, Teresa and Durot, Eric and Smith, Jeffrey and Renaud, Loïc and McKay, Pamela and Eyre, Toby A},
title = {High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {24},
pages = {2290--2302},
doi = {10.1200/jco-26-00947}
}
EUVIMED